Latest News of MLYS
We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate
By Yahoo! Finance |
1 month ago
Even with losses, shareholders can profit by investing in a good business at the right price. Mineralys Therapeutics (NASDAQ:MLYS) has a solid cash runway but increasing cash burn. Shareholders should...
Insider Sale at Mineralys Therapeutics Inc (MLYS): CFO and Secretary Adam Levy Sells Shares
By Yahoo! Finance |
4 months ago
On July 11, 2024, Adam Levy, CFO of Mineralys Therapeutics Inc (NASDAQ:MLYS), sold 10,757 shares at $13.14 each, now holding 247,611 shares. The company focuses on precision medicine for cardiovascula...
Mineralys Therapeutics Inc (MLYS) CEO Jon Congleton Sells 15,746 Shares
By Yahoo! Finance |
4 months ago
Mineralys Therapeutics Inc focuses on developing therapies for cardiovascular and cardiorenal diseases. Recent insider transactions, including significant share sales by Jon Congleton, have drawn atte...
-
Insider Sale: CEO Jon Congleton Sells Shares of Mineralys Therapeutics Inc (MLYS)
By Yahoo! Finance | 5 months agoJon Congleton, CEO of Mineralys Therapeutics Inc, sold 49,313 shares, now owning 926,958 shares. The company focuses on precision medicine for cardiovascular and kidney diseases. Insider activity show...
-
Mineralys Therapeutics Inc (MLYS) CEO Jon Congleton Sells 72,797 Shares
By Yahoo! Finance | 5 months agoMineralys Therapeutics Inc (NASDAQ:MLYS) is developing precision therapies for cardiovascular and kidney diseases. Recent insider transactions, including shares sold at $12.7 each, show a balanced act...
-
Insider Sale: CFO and Secretary Adam Levy Sells 96,815 Shares of Mineralys Therapeutics Inc (MLYS)
By Yahoo! Finance | 5 months agoAdam Levy, CFO of Mineralys Therapeutics Inc, sold 96,815 shares at $12.94 each, totaling $1,252,372.30. The company focuses on developing therapies for cardiovascular diseases....